ARS Pharmaceuticals (SPRY) Stock Statistics & Valuation Metrics

ARS Pharmaceuticals has a market cap or net worth of $724.91M. The enterprise value is $847.36M.

ARS Pharmaceuticals has 99,303,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

ARS Pharmaceuticals’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is -62.04%.

The current PE Ratio of ARS Pharmaceuticals is ―. ARS Pharmaceuticals’s PEG ratio is 0.00303.

In the last 12 months, ARS Pharmaceuticals had revenue of 84.28M and earned -171.30M in profits. Earnings per share was -1.74.

In the last 12 months, operating cash flow was -175.07M and capital expenditures -248.00K, giving a free cash flow of -175.32M billion.

ARS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

ARS Pharmaceuticals upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

ARS Pharmaceuticals as a current ratio of 7.28, with Debt / Equity ratio of 158.40%

In the past 12 months, ARS Pharmaceuticals has paid -80.00K in taxes.

ARS Pharmaceuticals EV to EBITDA ratio is -6.76, with an EV/FCF ratio of -7.03.

ARS Pharmaceuticals has $200.97M in cash and marketable securities with $97.11M in debt, giving a net cash position of $103.86M billion.

Gross margin is 77.10%, with operating margin of -212.92%, and net profit margin of -203.25%.

The average price target for ARS Pharmaceuticals is $27.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy